These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7747690)

  • 1. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.
    Sundberg S; Lilleberg J; Nieminen MS; Lehtonen L
    Am J Cardiol; 1995 May; 75(15):1061-6. PubMed ID: 7747690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S; Lehtonen L
    Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS; Harkin CP; Hettrick DA; Warltier DC
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
    Banfor PN; Preusser LC; Campbell TJ; Marsh KC; Polakowski JS; Reinhart GA; Cox BF; Fryer RM
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H238-48. PubMed ID: 17982006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropic support during experimental endotoxemic shock: part I. The effects of levosimendan on splanchnic perfusion.
    Cunha-Goncalves D; Perez-de-Sa V; Grins E; Dahm PL; Thörne J; Blomquist S
    Anesth Analg; 2009 Nov; 109(5):1568-75. PubMed ID: 19713249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine.
    Cunha-Goncalves D; Perez-de-Sa V; Larsson A; Thörne J; Blomquist S
    Anesth Analg; 2009 Nov; 109(5):1576-83. PubMed ID: 19713252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
    Põder P; Eha J; Antila S; Heinpalu M; Planken U; Loogna I; Mesikepp A; Akkila J; Lehtonen L
    Cardiovasc Drugs Ther; 2003; 17(5-6):451-8. PubMed ID: 15107600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
    Harkin CP; Pagel PS; Tessmer JP; Warltier DC
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
    Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G
    J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of the novel calcium sensitizer levosimendan in critically ill patients.
    Plöchl W; Rajek A
    Anaesth Intensive Care; 2004 Aug; 32(4):471-5. PubMed ID: 15675206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.
    Pagel PS; Hettrick DA; Warltier DC
    Br J Pharmacol; 1996 Oct; 119(3):609-15. PubMed ID: 8894186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemodynamic effects of levosimendan following cardiac surgery].
    Alvarez J; Taboada M; Rodríguez J; Caruezo V; Bouzada M; Campaña O; Bascuas B; Pérez-Paz J; Ginesta V
    Rev Esp Anestesiol Reanim; 2005; 52(7):389-94. PubMed ID: 16200918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.
    Lilleberg J; Nieminen MS; Akkila J; Heikkilä L; Kuitunen A; Lehtonen L; Verkkala K; Mattila S; Salmenperä M
    Eur Heart J; 1998 Apr; 19(4):660-8. PubMed ID: 9597417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function.
    Toivonen L; Viitasalo M; Sundberg S; Akkila J; Lehtonen L
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):664-9. PubMed ID: 10774799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.